Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma

被引:12
作者
Jain, Anish J. [1 ]
Maxwell, Jessica E. [1 ]
Katz, Matthew H. G. [1 ]
Snyder, Rebecca A. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
关键词
pancreatic cancer; pancreatic adenocarcinoma; neoadjuvant therapy; resectability; vascular resection; prehabilitation; CA 19-9 pancreatic cancer; chemotherapy switch; MESENTERIC VEIN RESECTION; 6-MINUTE WALK TEST; EN-BLOC RESECTION; VASCULAR RESECTION; PORTAL-VEIN; STAGING LAPAROSCOPY; ARTERIAL RESECTION; DUCTAL ADENOCARCINOMA; PREOPERATIVE THERAPY; POSTOPERATIVE COMPLICATIONS;
D O I
10.3390/cancers15164174
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary: Pancreatic ductal adenocarcinoma (PDAC) is a morbid malignancy with discouraging survival rates. Enthusiasm for pre-operative therapy (chemotherapy, radiation, chemoradiation) in the treatment of PDAC has grown, with many clinical guidelines recommending its use in patients with borderline resectable tumors. The purpose of this review is to discuss important surgical considerations for the use of pre-operative therapy in patients with pancreatic cancer undergoing curative intent surgery. These considerations include accurately determining tumor resectability, vascular resection, reconstruction when tumors involve surrounding vascular structures, and implementing pre-operative fitness programs to improve treatment outcomes. We also discuss methods to evaluate the response of PDAC to pre-operative therapy such as CA 19-9 levels, imaging studies, and others that are currently being studied for potential use in the future. Preoperative therapy can provide many benefits to patients with pancreatic cancer undergoing surgery, but a comprehensive understanding of several surgical considerations is needed. Pancreatic ductal adenocarcinoma (PDAC) is a challenging disease process with a 5-year survival rate of only 11%. Neoadjuvant therapy in patients with localized pancreatic cancer has multiple theoretical benefits, including improved patient selection for surgery, early delivery of systemic therapy, and assessment of response to therapy. Herein, we review key surgical considerations when selecting patients for neoadjuvant therapy and curative-intent resection. Accurate determination of resectability at diagnosis is critical and should be based on not only anatomic criteria but also biologic and clinical criteria to determine optimal treatment sequencing. Borderline resectable or locally advanced pancreatic cancer is best treated with neoadjuvant therapy and resection, including vascular resection and reconstruction when appropriate. Lastly, providing nutritional, prehabilitation, and supportive care interventions to improve patient fitness prior to surgical intervention and adequately address the adverse effects of therapy is critical.
引用
收藏
页数:20
相关论文
共 163 条
[1]   FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma [J].
Abdelrahman, Amro M. ;
Goenka, Ajit H. ;
Alva-Ruiz, Roberto ;
Yonkus, Jennifer A. ;
Leiting, Jennifer L. ;
Graham, Rondell P. ;
Merrell, Kenneth W. ;
Thiels, Cornelius A. ;
Hallemeier, Christopher L. ;
Warner, Susanne G. ;
Haddock, Michael G. ;
Grotz, Travis E. ;
Tran, Nguyen H. ;
Smoot, Rory L. ;
Ma, Wen Wee ;
Cleary, Sean P. ;
McWilliams, Robert R. ;
Nagorney, David M. ;
Halfdanarson, Thorvardur R. ;
Kendrick, Michael L. ;
Truty, Mark J. .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (09) :1023-+
[2]   Risk factors for complications after pancreatic head resection [J].
Adam, U ;
Makowiec, F ;
Riediger, H ;
Schareck, WD ;
Benz, S ;
Hopt, UT .
AMERICAN JOURNAL OF SURGERY, 2004, 187 (02) :201-208
[3]   Surgical Outcome Results From SWOG S1505 A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma [J].
Ahmad, Syed A. ;
Duong, Mai ;
Sohal, Davendra P. S. ;
Gandhi, Namita S. ;
Beg, Muhammad Shaalan ;
Wang-Gillam, Andrea ;
Wade, James L., III ;
Chiorean, Elena Gabriela ;
Guthrie, Katherine A. ;
Lowy, Andrew M. ;
Philip, Philip A. ;
Hochster, Howard S. .
ANNALS OF SURGERY, 2020, 272 (03) :481-486
[4]   The utility of nutritional supportive care with an eicosapentaenoic acid (EPA)-enriched nutrition agent during pre-operative chemoradiotherapy for pancreatic cancer: Prospective randomized control study [J].
Akita, Hirofumi ;
Takahashi, Hidenori ;
Asukai, Kei ;
Tomokuni, Akira ;
Wada, Hiroshi ;
Marukawa, Satoko ;
Yamasaki, Tomoyuki ;
Yanagimoto, Yoshitomo ;
Takahashi, Yusuke ;
Sugimura, Keijiro ;
Yamamoto, Kazuyoshi ;
Nishimura, Junichi ;
Yasui, Masayoshi ;
Omori, Takeshi ;
Miyata, Hiroshi ;
Ochi, Ayami ;
Kagawa, Ayano ;
Soh, Yuko ;
Taniguchi, Yuko ;
Ohue, Masayuki ;
Yano, Masahiko ;
Sakon, Masato .
CLINICAL NUTRITION ESPEN, 2019, 33 :148-153
[5]   Vascular resection and reconstruction for pancreatic malignancy: A single center survival study [J].
Al-Haddad, Mohammad ;
Martin, J. Kirk ;
Nguyen, Justin ;
Pungpapong, Surakit ;
Raimondo, Massimo ;
Woodward, Timothy ;
Kim, George ;
Noh, Kyung ;
Wallace, Michael B. .
JOURNAL OF GASTROINTESTINAL SURGERY, 2007, 11 (09) :1168-1174
[6]   Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer [J].
Allen, Victoria B. ;
Gurusamy, Kurinchi Selvan ;
Takwoingi, Yemisi ;
Kalia, Amun ;
Davidson, Brian R. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (11)
[7]   High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients [J].
Allenson, K. ;
Castillo, J. ;
San Lucas, F. A. ;
Scelo, G. ;
Kim, D. U. ;
Bernard, V. ;
Davis, G. ;
Kumar, T. ;
Katz, M. ;
Overman, M. J. ;
Foretova, L. ;
Fabianova, E. ;
Holcatova, I. ;
Janout, V. ;
Meric-Bernstam, F. ;
Gascoyne, P. ;
Wistuba, I. ;
Varadhachary, G. ;
Brennan, P. ;
Hanash, S. ;
Li, D. ;
Maitra, A. ;
Alvarez, H. .
ANNALS OF ONCOLOGY, 2017, 28 (04) :741-747
[8]   Delayed recovery after pancreaticoduodenectomy: A major factor impairing the delivery of adjuvant therapy? [J].
Aloia, Thomas E. ;
Lee, Jeffrey E. ;
Vauthey, Jean-Nicolas ;
Abdalla, Eddie K. ;
Wolff, Robert A. ;
Varadhachary, Gauri R. ;
Abbruzzese, James L. ;
Crane, Christopher H. ;
Evans, Douglas B. ;
Pisters, Peter W. T. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 204 (03) :347-355
[9]   Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival [J].
Altman, Ariella M. ;
Wirth, Keith ;
Marmor, Schelomo ;
Lou, Emil ;
Chang, Katherine ;
Hui, Jane Y. C. ;
Tuttle, Todd M. ;
Jensen, Eric H. ;
Denbo, Jason W. .
ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (12) :4108-4116
[10]   Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer [J].
Alva-Ruiz, Roberto ;
Yohanathan, Lavanya ;
Yonkus, Jennifer A. ;
Abdelrahman, Amro M. ;
Gregory, Lindsey A. ;
Halfdanarson, Thorvadur R. ;
Mahipal, Amit ;
McWilliams, Robert R. ;
Ma, Wen Wee ;
Hallemeier, Christopher L. ;
Graham, Rondell P. ;
Grotz, Travis E. ;
Smoot, Rory L. ;
Cleary, Sean P. ;
Nagorney, David M. ;
Kendrick, Michael L. ;
Truty, Mark J. .
ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (03) :1579-1591